Treating Prostate Cancer

Prostate Cancer affects one of six men

1 in 6 American men will be diagnosed with Prostate Cancer at an annual cost of  30,000 lives and $15B

Current remedies are few and ineffective

Only 5 drugs are FDA-approved
(2 chemotherapy drugs, 3 hormonal agents)

High Toxicity – severe side effects

Limited time effectiveness – tumor reacts/adapts to negate effectiveness of treatment

When this happens, the patient is terminal!

Capridine is a breakthrough

Capridine kills both hormone sensitive and insensitive cells, with 3 unique and powerful features:

High therapeutic index (small dose yields high impact)

Low blood and bone marrow toxicity (reducing side effects)

Re-enables previous drugs to resume effectiveness

Which significantly increases survival prospects!

Provax is a preventative vaccine for prostate  cancer recurrence

Synthetic peptide vaccine (no refrigeration required) that mimics cancer proteins, induces the host’s immune response directed against multiple cancer-specific proteins

Easily manufactured, small molecule drug

Preclinical studies complete

Expected to eliminate micrometastatic and residual disease and hence prevent recurrence

 

 

 


Patents

9-alkylamino-1-nitroacridine derivatives (Capridines)
United States Patent # 6,589,961

Nitroacridine tumor inhibitor composition
United States Patent #7,622,478B2

Immunotherapy for prostate cancer using recombinant bacille Calmette-Guerin expressing prostate specific antigens
United States Patent # 7,718,166

Immunogens for treatment of
neoplastic and infectious disease
United States Patent # 8,969,012
United States Patent # 8,088,569


Pending

Synthetic toll-like receptor-4 (TLR-4)
agonist peptides
PENDING Application number PCT/US2013/025568